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ABSTRACT: We designed a library of 24 cyclic peptides containing arginine
(R) and tryptophan (W) residues in a sequential manner [RnWn] (n = 2−7)
to study the impact of the hydrophilic/hydrophobic ratio, charge, and ring
size on the antibacterial activity against Gram-positive and Gram-negative
strains. Among peptides, 5a and 6a demonstrated the highest antimicrobial
activity. In combination with 11 commercially available antibiotics, 5a and 6a
showed remarkable synergism against a large panel of resistant pathogens.
Hemolysis (HC50 = 340 μg/mL) and cell viability against mammalian cells
demonstrated the selective lethal action of 5a against bacteria over
mammalian cells. Calcein dye leakage and scanning electron microscopy
studies revealed the membranolytic effect of 5a. Moreover, the stability in
human plasma (t1/2 = 3 h) and the negligible ability of pathogens to develop
resistance further reflect the potential of 5a for further development as a peptide-based antibiotic.
increased immunological responses.12 AMPs provide several
advantages over traditional antibiotics, such as poor induction
of resistance; broad-spectrum activity against a wide variety of
bacteria, fungi, protozoans, viruses, and surprisingly even
cancerous cells; lower toxicity to the host cells; being less
harmful to both the environment and consumers; synergistic
effects on the antimicrobial activity of antibiotics; and rapid
killing or inhibiting of the pathogens.13−20
Most of the AMPs are cationic and have net positive charges
ranging from +2 to +9 with an amphipathic arrangement that
involves separate hydrophobic and hydrophilic domains.21,22
The hydrophilic face consisting of polar cationic residues, such
as arginine (R) and lysine (K), provides the source of
electrostatic interactions between the peptide and the
lipopolysaccharide (LPS) or lipoteichoic acid (LTA) that are
the negatively charged elements of the microbial cell
membrane.23,24 On the other hand, the hydrophobic face is
composed of nonpolar residues, such as tryptophan (W),
alanine (A), glycine (G), and leucine (L), providing lipophilicity that ultimately disturbs the membrane and creates
pores across the membrane leading to cell death.23,25,26 Some
AMPs cross the membrane without destroying it27,28 and act

1. INTRODUCTION
Antibiotics are valuable tools for fighting against bacterial
infections. However, antibiotic resistance1 is a naturally
occurring process. According to the CDC 2019 Antibiotic
Resistance (AR) Threats Report, infections caused by
antibiotic-resistant germs surpassed 2.8 million, with a
mortality rate exceeding 35,000 in the U.S. each year.1 Many
of these infections have no treatment options. Bacterial
infections spread around us in the communities, food supplies,
water, and soil. However, serious infections, especially with
multidrug-resistant pathogens, are widely dispersed in healthcare facilities like hospitals, clinics, or nursing homes, called
healthcare-associated infections (HAIs).1,2 Unfortunately, antibiotics innovation and development entered a dark age after
the 1960s because of the rapid emergence of resistance.3
Consequently, the generation of novel medications to control
and treat infections caused by multidrug-resistant pathogens
has become a pressing priority for the scientific community.
In recent years, antimicrobial peptides (AMPs) have been
considered the best alternative to overcome multidrug-resistant
pathogen infections.4−6 The discovery of AMPs dates back to
1939, with gramicidin as the first recognized AMP.7 AMPs are
identified from the innate immune system for multicellular
organisms. They are produced as the first line of defense
against invading microbial infections.8,9 As part of the innate
immunity, AMPs directly kill bacteria by acting at the
membrane10 or via inhibiting macromolecular functions,
leading to bacterial cell death.11 Furthermore, AMPs can kill
pathogens by directing cytokines to the infection area, causing
© XXXX The Authors. Published by
American Chemical Society
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Figure 1. Representative chemical structures of cyclic peptides [R4W4] (1), [R5W4] (5a), [R5W5] (5b), [R6W4] (6a), and [R6W5] (6b).

on intracellular targets, for instance, binding to RNA, DNA, or
histones,29−31 stopping DNA-dependent enzymes,32 preventing the synthesis of essential outer membrane proteins,33 and
binding to the ribosome and lipid II.34,35

Peptide-based antibiotics have been approved by the U.S.
Food and Drug Administration (U.S. FDA) and are already on
the market, and some others are in the clinical trial stage. For
instance, vancomycin is one of the most important frontline
B
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Scheme 1. Solid-Phase Synthesis of [R5W4] (5b) as a Representative Example

antibiotics approved by the U.S. FDA in 1958 to treat
infections caused by Gram-positive bacteria, especially
methicillin-resistant Staphylococcus aureus (MRSA). It was
isolated by a fungus named Streptomyces orientalis and
contained impurities.36 Vancomycin has been used intravenously. Daptomycin was approved in 2003 to treat infections
caused by Gram-positive bacteria.37 In addition to gramicidin,
polymyxin, and bacitracin, three more peptide-based antibiotics, telavancin (2009),38 dalbavancin (2014),39 and
oritavancin (2014),39 have been approved by the U.S. FDA
for the treatment of S. aureus infections.
Meanwhile, pharmaceutical companies are expanding their
efforts to use AMPs as commercially available medications.40
For example, NP339 (Novamycin) is being studied by
Novabiotics Company in the preclinical stage.41 Another
example is LTX-109 (Lytixar), developed for topical treatments by Lytix Biopharma Company, which is in the phase I/II
trial for the treatment of S. aureus infection, including MRSA.42
Despite the many advantages of AMPs, they also suffer from
some shortfalls, such as hemolytic activity toward human red
blood cells, protease instability, salt and serum sensitivity, and
high production cost.9,43 Therefore, developing more effective
AMPs to overcome these limitations is necessary to enhance
their therapeutic applications. For maximum efficacy in vivo
and in vitro, many strategies have been employed to improve
the overall properties of AMPs, such as optimization of
sequences, truncation, modification of hybrid analogs, and
redesign of parent peptide sequences via amino acid
substitution.44−47 These simple strategies assist in overcoming
barriers and speed up the development of the clinical
application of AMPs.27,48,49
Many AMPs contain W and Residues. These residues are
known to mediate membrane disruption and/or cell entry.56,57
R and W residues possess some important chemical features
that make them suitable components of antimicrobial peptides.
R side chains are always predominantly charged even when

buried in a hydrophobic microenvironment that is because of
the high equilibrium acid dissociation constant (pKa value) of
the arginine guanidinium group of 13.8 ± 0.1.58 The unusual
ability of the R side chain to remain ionized, unlike the other
ionizable amino acids such as lysine and even in microenvironments that are typically incompatible with charges, is attributed
to three main reasons: (I) the positive charge delocalization of
the guanidinium moiety over many atoms involved in a
conjugated Y−π system,59 (II) the conformational flexibility of
the R long side chain,60 and (III) its high intrinsic pKa value.58
Tryptophan is hydrophobic due to its aromatic uncharged
indole side chain, which possesses an extensive π−electron that
gives rise to a significant quadrupole moment, resulting in
negatively charged clouds enabling tryptophan to participate in
cation−π interactions.61 The cationic guanidinium group from
the R side chain can be bonded to the aromatic pi face of W
through cation−π noncovalent forces to complement each
other well for antimicrobial peptides.55
Several quantitative structure−activity relationships (QSAR)
studies demonstrated the importance of amino acid
composition to antimicrobial activity, especially the model
peptides with R and W as repeating pharmacophore units.62,63
Moreover, QSAR studies indicated that RW motifs could
retain activity despite a lack of defined secondary structure.64,65
Our group has previously discovered and reported that
cyclic peptides [R4W4] (Figure 1) and [W4KR5] containing W
and R residues assembled in an ordered manner to have
antibacterial activity against multidrug-resistant pathogens,
especially, against Gram-positive bacteria.50,51 Moreover,
[R4W4] showed cell-penetrating properties in eukaryotic cells
and bactericidal effects in the [R4W4]/tetracycline combination against MRSA and E. coli.50 Cyclic peptides showed higher
antibacterial activities compared to the corresponding linear
counterparts. Arginine and tryptophan with an L-configuration
were required to generate optimal activity.52 Moreover,
[R4W4] was used to develop covalent conjugates with
C

https://doi.org/10.1021/acs.jmedchem.2c01469
J. Med. Chem. XXXX, XXX, XXX−XXX

Journal of Medicinal Chemistry

pubs.acs.org/jmc

Article

Table 1. Antibacterial Activity of Designed Cyclic Peptides
MIC (μg/mL)a
b

c

peptide
code

peptide
sequence

MRSA (ATCC BAA1556)

K. pneumoniae (ATCC
BAA-1705)

P. aeruginosad (ATCC
27883)

E. colid (ATCC
25922)

HC50f
(μg/mL)

therapeutic
indexi

1
2a
2b
3a
3b
3c
3d
3e
3f
4a
4b
4c
4d
5a
5b
5c
5d
6a
6b
6c
6d
7a
7b
7c
7d
Mero
Vanco
Poly B

[R4W4]
[R2W3]
[R2W4]
[R3W3]
[R3W4]
[R3W5]
[R3W6]
[R3W7]
[dR3W7]
[dR4W4]
[R4W5]
[R4W6]
[R4W7]
[R5W4]
[R5W5]
[R5W6]
[R5W7]
[R6W4]
[R6W5]
[R6W6]
[R6W7]
[R7W4]
[R7W5]
[R7W6]
[R7W7]
meropenem
vancomycin
polymyxin B

4
32
64
16
8
128
64
256
64
8
8
128
256
4
4
>256
>256
8
8
16
64
16
8
32
16
2
1
64

32
256
256
64
64
128
128
64
256
64
128
256
256
32
32
>256
>256
64
64
64
256
64
NDe
NDe
NDe
16
512
1

64
256
256
128
256
64
256
256
256
64
128
128
>256
32
32
>256
>256
16
16
128
>256
32
NDe
NDe
NDe
1
256
1

16
256
256
32
32
128
64
256
256
16
64
128
128
16
16
>256
>256
32
32
64
128
32
64
64
32
1
256
2

175
120
85
155
105
80
65
60
NDe
110
100
75
60
340
230
140
115
265
255
170
85
190
175
170
140
NDe
NDe
NDe

43.75
3.75
1.33
9.69
13.13
0.63
1.02
0.23
NDe
13.75
12.50
0.59
0.23
85.00
57.50
>0.54
>0.45
33.12
31.88
10.63
1.33
11.88
21.88
5.31
8.75

a

The minimum inhibitory concentration (MIC) is the lowest concentration of the peptides that inhibited bacterial growth. bMethicillin-resistant
bacterial strain. cImipenem-resistant bacterial strain. dNonresistant strain. eND, not determined. fHC50 is the concentration of a peptide in μg/mL
at which 50% hemolysis was observed. iThe therapeutic index is calculated based on HC50/MIC against MRSA. The table presents the data of three
independent experiments performed in triplicate.

antibiotics. However, the conjugation diminished the activity.53
The use of [R4W4], along with first-line antituberculosis
medications, reduced the side effects of antibiotics and
improved the immune responses to get rid of the active
Mycobacterium tuberculosis (Edman strain) infection. The
activity was determined against infected peripheral blood
mononuclear cells (PBMCs) by quantification of the intracellular survival of the bacteria.54
In this study, a library of 24 cyclic peptides was rationally
designed based on the [RnWn] sequence as the model scaffold
to study the impact of the hydrophilic/hydrophobic ratio,
charge, and ring size on antibacterial activity. This study
assisted in establishing a structure−activity relationship (SAR)
to understand further the role of R and W residues and the
cationic/hydrophobic ratio on antibacterial activity and other
essential properties. Designed peptides were successfully
synthesized using Fmoc/tBu solid-phase peptide synthesis.
All synthesized peptides were evaluated for their antibacterial
efficacy against Gram-positive and Gram-negative bacteria,
including multidrug-resistant strains. The salt effect and
synergistic activity were also evaluated for a better understanding of the role of the cyclic peptide as a promising
alternative antibacterial agent and the revival of traditional
antibiotics. AMPs have been known to achieve their
antibacterial effect in a number of different modes; however,

an initial interaction with the bacterial membrane is
necessary.10,55 The interactions with bacterial membranes
were also evaluated using calcein dye leakage and scanning
electron microscopy (SEM).

2. RESULTS AND DISCUSSION
2.1. Chemistry. We designed a library of cyclic amphiphilic
peptides using R and W residues in an ordered sequential
manner [RnWn] (n = 2−7) by systematically changing the
number of R and W residues to study the impact of the
hydrophilic/hydrophobic ratio, charge, and ring size on
antibacterial activity. Moreover, this study aimed to determine
the optimal number of cationic and hydrophobic residues
required to target bacteria effectively and to obtain a promising
antibacterial agent. Figure 1 shows representative cyclic
peptides in this class.
A representative example of the synthetic process for the
synthesis of compound 5b is depicted in Scheme 1. The
peptides were synthesized using Fmoc/tBu solid-phase peptide
synthesis. The first step in the synthesis of peptides was
assembling W and R on the tryptophan-preloaded HTrp(Boc)-2-chlorotrityl resin as a solid support. Assembly
was started with W residues followed by R residues using
coupling and deprotecting reagents, as described in the
Experimental Section.
D
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Cyclic peptides were obtained after the cleavage of the
assembled side chain-protected linear peptides from the resin
followed by N- to C-cyclization in the solution phase. The
assembled side chain-protected peptide was detached from the
resin in the presence of trifluoroethanol (TFE)/acetic acid/
dichloromethane (DCM) [2:1:7 (v/v/v)]. After evaporation of
the solution, the resultant solid was dissolved in an anhydrous
dimethylformamide (DMF)/DCM mixture and stirred with 1hydroxy-7-azabenzotriazole (HOAt) and N,N-diisopropylcarbodiimide (DIC) under nitrogen overnight at room temperature to accomplish the cyclization. The final cleavage for the
cyclic peptides was achieved in the presence of a freshly
prepared cleavage cocktail R containing trifluoroacetic acid
(TFA)/thioanisole/1,2-ethanedithiol (EDT)/anisole
(90:5:3:2, v/v/v/v).
The purification process for synthesized cyclic peptides
proceeded via reversed-phase high-performance liquid chromatography (RP-HPLC). The purity of compounds was found
to be ≥95%. All synthesized peptides were characterized using
high-resolution matrix-assisted laser desorption/ionization
(MALDI) mass spectroscopy.
2.2. Antibacterial Activity. 2.2.1. MIC Determination.
AMPs can play multiple roles in treating chronic infections and
work as antimicrobial, antiattachment, and antibiofilm
agents.66 Structural properties of AMPs, such as the size,
sequence, cationic nature, and amphipathicity, help to possess
many modes of action. In general, AMPs affect the transmembrane potential via increasing membrane permeation and
causing cell lysis leading to cell death. Moreover, they can
neutralize or disaggregate the lipopolysaccharide, the main
endotoxin responsible for Gram-negative infections.66,67 The
amphipathic structure is crucial for the bactericidal activity of
AMPs.68
Herein, we developed a library of 24 cyclic peptides rich in R
and W residues and evaluated them as AMPs based on the
following rationale. The positively charged guanidine unit of R
facilitates the initial binding of peptides to the membrane
surfaces via electrostatic interactions. Bacterial membranes
consist of negatively charged phospholipid head groups like
phosphatidylglycerol, cardiolipin, or phosphatidylserine and
display high affinity for cationic positively charged R
residues.69 Additionally, R provides the hydrogen bonding
geometry necessary for membrane translocation.56 Moreover,
W demonstrates a crucial function in membrane association
due to its substantial preference for the interfacial regions of
lipid bilayers, leading to the enhancement of the antimicrobial
properties of the peptides.51,52,70
The minimum inhibitory concentration (MIC) values for
synthesized cyclic peptides were measured using a microbroth
dilution assay to determine the antibacterial activity against
Gram-positive and Gram-negative strains. Four bacterial
strains, including two multidrug-resistant strains (Grampositive methicillin-resistant Staphylococcus aureus (S. aureus
BAA-1556, MRSA) and Gram-negative Klebsiella pneumoniae
(K. pneumoniae BAA-1705)) and two nonresistant strains
(Gram-negative Pseudomonas aeruginosa (P. aeruginosa 27883)
and Escherichia coli (E. coli 25922)) were used for antibacterial
screening (Table 1). Meropenem, vancomycin, and polymyxin
B were used as antibiotic controls.
Peptides [R2W3] 2a and [R2W4] (2b) with two R residues
exhibited a moderate activity against MRSA. The antimicrobial
activity reduced from 32 μg/mL for peptide 2a to 64 μg/mL
for peptide 2b with one extra W residue. Both peptides 2a and

Article

2b showed negligible activity against all tested Gram-negative
strains.
Peptides 3a−f have three R residues. Peptides [R3W3] 3a
and [R3W4] (3b) showed a higher activity against MRSA
compared to the corresponding peptides 2a and 2b composed
of two R residues and showed MIC values of 16 and 8 μg/mL,
respectively. The activity against Gram-negative bacteria was
also slightly enhanced, especially against E. coli (25922), with
an MIC value of 32 μg/mL for both 3a and 3b. However, the
antimicrobial activity considerably decreased with increasing
the number of W residues in peptides 3c−f against all tested
strains. The same pattern was also observed in peptides 5a−d,
6a−d, and 7a−d, especially against MRSA (Table 1).
When L-Arg in [R4W4] (1) and [R3W7] (3e) was replaced
with D-Arg in peptides [dR3W7] (3f) and [dR4W4] (4a), there
was no difference in activity against P. aeruginosa and E. coli.
However, [dR4W4] (4a) showed 2-fold less activity against
MRSA and K. pneumoniae when compared with [R4W4] (1).
[dR3W7] (3e) exhibited 4-fold more activity against MRSA but
4-fold less activity against K. pneumoniae when compared with
[R3W7] (3e). These data indicated that the stereochemistry of
the natural amino acids affects their activity in MRSA and K.
pneumoniae.
Peptides [R3W3] (3a), [R4W4] (1), and [R5W5] (5b) that
have an equal number of hydrophilic and hydrophobic residues
showed an enhanced antimicrobial activity with increasing the
recurring theme from 3 to 5 R/W (with a ring containing 6 to
10 amino acid residues). However, further expansion in the
ring size (12−14 amino acid residues) in [R6W6] (6c) and
[R7W7] (7d) led to a reduced antimicrobial activity.
Among all the peptides, [R5W4] (5a), [R5W5] (5b), [R6W4]
(6a), and [R6W5] (6b) were found to have MIC values of 4−8,
32−64, 16−32, and 16−32 μg/mL against MRSA, K.
pneumoniae, P. aeruginosa, and E. coli, respectively. Compound
5a was two-fold more potent than [R4W4] (1) against P.
aeruginosa (ATCC 27883) and had about two-fold higher
HC50. Compounds 6a and 6b were 4-fold more potent than
[R4W4] (1) against P. aeruginosa but two-fold less active
against other bacteria. However, compounds 5a and 5b were 2fold more potent than 1 against P. aeruginosa and had similar
activity against other bacteria. In this case, increasing the
number of R and W residues did not affect the antibacterial
activity. However, the peptides with a lower number of W
residues (5a vs 5b and 6a vs 6b) showed less hemolytic
activity. Among all the compounds, compound 5a showed the
highest therapeutic index (85.00) calculated for MRSA (Table
1). Based on the highest therapeutic index values, we selected
peptides 5a, 5b, 6a, and 6b for further studies.
2.2.2. Broad-Spectrum ESKAPE Screening. ESKAPE
pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas
aeruginosa, and Enterobacter species) are nosocomial pathogens
that demonstrate multidrug resistance and virulence and are
capable of escaping the action of antibiotics.71 The World
Health Organization (WHO) has listed ESKAPE among the
pathogens that urgently require new antibiotics.72 AMPs have
broad-spectrum activity against a wide range of pathogens via
physical damage of bacteria membranes, making it difficult for
bacteria to develop resistance.73 Considering the priority of
curing ESKAPE pathogens, AMPs could be a promising
antibiotic alternative to fight against them. Numerous AMPs
have been reported to exhibit promising antimicrobial potency
against ESKAPE pathogens in vitro and in vivo.74−77
E
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were 2-fold better than daptomycin. Furthermore, peptide 5a
exhibited a comparable activity against the nonresistant strain
E. faecium (ATCC 27270) with an MIC value of 4 μg/mL
when compared with daptomycin.
Peptide 6a demonstrated an MIC value of 1 μg/mL and a 4fold improvement against S. pneumoniae (ATCC 49619) when
compared to daptomycin (MIC = 4 μg/mL). Compound 6a
also showed a promising antibacterial efficacy against Bacillus
subtilis (ATCC 6633) with an MIC value of 1 μg/mL.
Peptides 5b, 6a, and 6b showed a comparable antimicrobial
activity with daptomycin against E. faecalis (ATCC 29212)
with an MIC value of 16 μg/mL. However, peptides 5b and 6b
showed a moderate antimicrobial activity against the multidrug-resistant strain S. pneumoniae (ATCC 51938) and
nonresistant S. pneumoniae (49619) with MIC values of 64
and 32 μg/mL, respectively. Peptide 6a displayed a moderate
antimicrobial potency against multidrug-resistant E. faecalis
(ATCC 51575) with an MIC of 32 μg/mL. Peptides 5b, 6a,
and 6b showed an antibacterial activity against the Grampositive strains S. aureus (ATCC 29213), E. faecium (ATCC
27270), E. faecium (ATCC 700221), and B. cereus (ATCC
13061) with MICs of 4−16 μg/mL.
When evaluating the data against Gram-negative bacteria,
peptides 5a, 5b, and 6a displayed a promising antimicrobial
activity with an MIC value of 16 μg/mL against the multidrugresistant strain E. coli (ATCC BAA-2452). Furthermore,
peptides 6a and 6b showed an MIC of 16 μg/mL against
multidrug-resistant P. aeruginosa (ATCC BAA-1744) and the
nonresistant strain P. aeruginosa (ATCC 10145). All tested
peptides showed a moderate antibacterial activity against the
rest of the tested Gram-negative bacterial strains (K.
pneumoniae (ATCC 13883) and Acinetobacter baumannii
(ATCC BAA-1605)) with MICs of 32−64 μg/mL, showing
less activity than polymyxin B. Based on the broad-spectrum
ESKAPE antibacterial screening results, lead peptides 5a and
6a were selected for further studies.
The activity of 5a against additional ESKAPE strains,
including clinical isolates, was examined by JMI Laboratories
(North Liberty, IA) subcontracted by the National Institute of
Health (Table 3). The 2021 SENTRY antimicrobial
surveillance program provided the clinical isolates for the
work conducted by JMI Laboratories (Table S2, Supporting
Information). The data were consistent with those in Table 2.
The activity of compound 5a varied according to the bacterial
species, with the highest activity detected against S. aureus and
the lowest potency observed against K. pneumoniae. The E. coli,
P. aeruginosa, and S. aureus sets were composed of 1 generally
susceptible strain and 2 more resistant strains/isolates. For
these small species sets, there was no evidence that the activity
of the 5a was impacted by the resistance phenotypes present.
2.2.3. Minimum Bactericidal Concentration (MBC) Determination. For further determination of the antibacterial
potential of lead peptides 5a, 5b, 6a, and 6b, we determined
their minimum bactericidal concentration (MBC). MBC is the
lowest concentration of an antibacterial agent required to kill
99.9% of the final inoculum after incubation over a fixed period
(generally for 24 h) and is also known as the minimal lethal
concentration (MLC).78 Four bacterial strains were used for
MBC screening (Table 4) that include two multidrug-resistant
strains (Gram-positive MRSA (ATCC BAA-1556) and Gramnegative K. pneumoniae (ATCC BAA-1705)) and two
nonresistant strains (Gram-negative P. aeruginosa (ATCC
27883) and E. coli (ATCC 25922)). Meropenem, polymyxin

Based on the therapeutic index values of the peptide library
(Table 1), we selected four promising peptides 5a, 5b, 6a, and
6b for screening against a broad range of antibiotic-resistant
Gram-positive and Gram-negative bacteria representing the
ESKAPE panel (Table 2). Daptomycin and polymyxin B were
Table 2. Minimum Inhibitory Concentrations of 5a, 5b, 6a,
and 6b against ESKAPE Pathogens
MIC (μg/mL)a
bacterial strain
S. aureus (ATCC
29213)b
E. faecium (ATCC
27270)b
E. faecium (ATCC
700221)b,c
E. faecalis (ATCC
29212)b
E. faecalis (ATCC
51575)b,d
S. pneumonia
(ATCC 49619)b
S. pneumonia
(ATCC 51938)b,e
Bacillus subtilis
(ATCC-6633)b
Bacillus cereus
(ATCC-13061)b
E. coli (ATCC
BAA-2452)f,g
K. pneumoniae
(ATCC 13883)f
P. aeruginosa
(ATCC BAA1744)f,h
P. aeruginosa
(ATCC 10145)f
Acinetobacter
baumannii
(ATCCBAA1605)f,i

daptomycin

polymyxin B
j

5a

5b

6a

6b

4

4

8

8

1

ND

4

ND

4

8

8

8

2

ND

4

8

4

16

16

ND

8

16

16

16

4

ND

16

16

32

16

4

ND

2

64

1

32

8

ND

2

64

2

32

0.5

ND

4

4

1

4

2

ND

16

4

16

8

ND

1

16

16

16

32

ND

1

32

64

64

64

ND

2

32

32

16

16

ND

2

32

32

16

16

ND

1

32

32

32

32
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a

The minimum inhibitory concentration (MIC) is the lowest
concentration of the peptides that inhibited bacterial growth.
b
Gram-positive strain. cVancomycin- and teicoplanin-resistant
bacterial strain. dGentamicin-, streptomycin-, and vancomycinresistant bacterial strain. ePenicillin-, clindamycin-, cotrimoxazole-,
and erythromycin-resistant bacterial strain. fGram-negative strain.
g
Carbapenem, New Delhi metallo-beta-lactamase (NDM-1)-positive
resistant bacterial strain (CRE (NDM-1)). hCarbapenem-resistant
bacterial strain. iResistant to ceftazidime, gentamicin, ticarcillin,
piperacillin, aztreonam, cefepime, ciprofloxacin, imipenem, and
meropenem. jND, not determined. The table presents the data of
three independent experiments performed in triplicate.

selected as positive controls against Gram-positive and Gramnegative bacteria, respectively. Generally, the results showed
that the lead peptides demonstrated a promising antibacterial
activity against Gram-positive bacteria and a moderate activity
against Gram-negative strains.
Peptides 5a and 6a showed a significant antibacterial activity
against Gram-positive multidrug-resistant strain Streptococcus
pneumoniae (S. pneumoniae) (ATCC 51938) with an MIC
value of 2 μg/mL, which was a 4-fold improvement when
compared with daptomycin. Moreover, 5a showed a significant
antimicrobial activity against nonresistant strains S. pneumoniae
(ATCC 49619) and Enterococcus faecalis (E. faecalis) (ATCC
29212) with MIC values of 2 and 8 μg/mL, respectively, which
F
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against MRSA (ATCC BAA-1556), which was 2-fold better
than the parent peptide [R4W4]. All tested peptides showed
reduced MBC values against P. aeruginosa (ATCC 27883) with
4−8-fold enhancement in activity compared to [R4W4].
However, peptide 6a showed the highest bactericidal potency
against P. aeruginosa (ATCC 27883) with an 8-fold enhancement in activity compared to [R4W4]. Peptide 5a demonstrated an MBC of 16 μg/mL against E. coli (ATCC 25922)
with a 2-fold enhancement in activity compared to [R4W4]. In
contrast, 6a showed a bactericidal activity at 32 μg/mL,
comparable to [R4W4] against E. coli (ATCC 25922). Based
on these results, peptides 5a and 6a were considered as the
lead peptides for further studies.
2.3. Salt Sensitivity. Prior studies have indicated that
positive charges facilitate antimicrobial peptide binding to the
negatively charged bacterial membranes through electrostatic
interactions.79 However, the presence of other positively
charged entities, like salts, can weaken this electrostatic
interaction.80 Thus, the antibacterial activities of the lead
peptides 5a and 6a were examined in the presence of different
physiological salts at physiologic concentrations and fetal
bovine serum compared with media only (Table S3,
Supporting Information). Peptides 5a and 6a retained their
antimicrobial potency in the presence of monovalent (Na+ and
K+), divalent (Ca2+), and trivalent (Fe3+) at physiological
concentrations, suggesting that the cationic character had no
effect on the peptide’s antimicrobial activity, presumably due
to the presence of the bulky side chain of W that could
enhance the association of the AMP with the bacterial
membrane,80,81 contributing to the antibacterial effect in the
presence of salts. However, there was a slight increase in the
antibacterial activity of 5a and 6a by 2-fold against all tested
strains in the presence of NH4+ and Mg2+. Peptides 5a and 6a
showed MICs of 2 and 4 μg/mL against MRSA, respectively,
in the presence of NH4+ and Mg2+. Peptides 5a and 6a showed
an antibacterial activity against Gram-negative strains P.
aeruginosa and E. coli in the presence of NH4+ and Mg2+
with MICs of 8−16 μg/mL. However, 6a exhibited a moderate
activity against K. pneumoniae (ATCC BAA-1705) with an
MIC value of 32 μg/mL. Moreover, peptide 5a showed a 2fold enhancement in antibacterial efficacy against K. pneumoniae (ATCC BAA-1705) with an MIC of 16 μg/mL in the
presence of divalent Ca2+.
2.4. Combination Therapy. Multidrug-resistant bacteria
are considered a major threat to hospitalized patients and have

Table 3. Minimum Inhibitory Concentration of 5a against
Additional ESKAPE Pathogens Including Clinical Isolates
MIC (μg/mL)a
bacterial strain
S. aureus (1193193)b
S. aureus (1195201)c
S. aureus (ATCC 29213)d
E. coli (1191008)e
E. coli (ATCC 25922)f
E. coli (ATCC BAA-2452)g
K. pneumoniae (ATCC 700603)h
K. pneumoniae (1188718)i
K. pneumoniae (ATCC BAA 1705)j
P. aeruginosa (1191191)k
P. aeruginosa (1188712)k
P. aeruginosa (ATCC 27853)f
Acinetobacter baumannii (NCTCl 13304)m
Acinetobacter baumannii-calcoaceticus species complex
(1188767)n
Acinetobacter baumannii-calcoaceticus species complex
(1189854)n

cefepime

5a

16
>32
2
8
0.06
32
1
8
32
32
8
1
32
32

4
4
4
16
16
16
>64
>64
>64
32
16
32
16
32

32

16

Article

a

The minimum inhibitory concentration (MIC) is the lowest
concentration of the peptides that inhibited bacterial growth.
b
Methicillin-resistant Staphylococcus aureus. cMultidrug-resistant
Staphylococcus aureus. dMethicillin-susceptible Staphylococcus aureus.
e
Multidrug-resistant E. coli. fWild type. gCarbapenem, New Delhi
metallo-beta-lactamase (NDM-1)-positive resistant bacterial strain
(CRE (NDM-1)). hExtended-spectrum β-lactamase (ESBL) (K.
pneumoniae ATCC 700603 produces SHV-18). iMultidrug-resistant
K. pneumoniae. jCarbapenem-resistant Enterobacterales (KPC-2).
k
Multidrug-resistant P. aeruginosa. lNational Collection of Type
Cultures. mCarbapenem-resistant Acinetobacter baumannii (CRAB)
(OXA-27). nMultidrug resistance.

B, daptomycin, and ciprofloxacin were used as control
antibiotics. For better comparative analysis, we included
conventional small-molecule antibiotics as well as standard
lipopeptide antibiotics as positive controls.
Peptide 5a showed bactericidal activity with an MBC value
of 8 μg/mL against MRSA (ATCC BAA-1556), comparable to
meropenem. On the other hand, peptides 5a and 6b displayed
an MBC value of 64 μg/mL against K. pneumoniae (ATCC
BAA-1705) comparable to meropenem. Peptide 5b killed
bacteria at 32 μg/mL with a 2-fold improvement compared to
meropenem against K. pneumoniae (ATCC BAA-1705).
Peptides 5b, 6a, and 6b demonstrated MBCs of 16 μg/mL

Table 4. Minimum Bactericidal Concentrations (MBC) of Cyclic Peptides 5a, 5b, 6a, and 6b
MBC (μg/mL)a
peptide code peptide sequence
5a
5b
6a
6b
1
Mero
Dapto
Poly B
Cipro

[R5W4]
[R5W5]
[R6W4]
[R6W5]
[R4W4]
meropenem
daptomycin
polymyxin B
ciprofloxacin

b

c

MRSA (ATCC BAA-1556) K. pneumoniae (ATCC BAA-1705) P. aeruginosad (ATCC 27883) E. colid (ATCC 25922)
8
16
16
16
32
8
8
NDe
32

64
32
128
64
64
64
NDe
2
16

32
32
16
32
128
4
NDe
2
8

16
64
32
128
32
2
NDe
4
16

a

The minimum bactericidal concentration (MBC) is the lowest concentration of the peptides that completely kill the bacteria. bMethicillinresistant bacterial strain. cImipenem-resistant bacterial strain. dNonresistant strain. eND = not determined. The table presents the data of three
independent experiments performed in triplicate.
G
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been associated with high mortality rates, especially those
caused by Gram-negative pathogens. The spread and danger of
multidrug-resistant infection force the medical community to
rely on additional broad-spectrum antibiotics to cure these
infections, leading to more resistance.82 This has become a
concerning issue because of the limited options of antimicrobial agents currently available to fight against these
pathogens.83−85 The lack of effective antibiotic options in
the market is because of slow pace, high cost, and low selling
prices of new antibiotics.86 Combination therapy can deal with
and overcome antimicrobial resistance and repurpose existing
antibiotics.87 Thus, designing antimicrobial combination
therapies to identify novel synergistic drug interactions is a
promising approach to fight against or delay bacterial
resistance.
Recently, the scientific community has paid much attention
to AMPs as promising alternatives to antibiotics, especially
against multidrug-resistant bacteria due to their broadspectrum antibacterial activity and unique nonspecific
membrane rupture mechanism, which prevents or retards the
ability of bacteria to develop resistance.17 Due to their potency
as antimicrobial agents, many AMPs have been subjected to
clinical trials.88
Multiple AMPs are released during immune responses in
vivo to fight bacterial infections, suggesting that the
combinations that have synergistic interactions could be
more lethal. Moreover, previous reports indicated that using
antibiotic combinations supports antibacterial efficacy and aids
in preventing bacterial resistance.89,90 The use of AMPs along
with commercially available antibiotics has been proposed as
an alternative option leading to antibiotic revival. Prior studies
indicated that AMPs act in synergy with traditional antibiotics
against multidrug-resistant bacteria.91−93 Based on the
promising antibacterial activities of 5a and 6a as AMPs, we
investigated whether they can be used in combination with
other antibiotics.
2.4.1. Antibacterial Evaluation of Peptides and Antibiotic
Physical Mixtures. The physical mixtures of a wide range of
frontline antibiotics with lead peptides (5a and 6a; 1:1 w/w)
were screened against four bacterial strains. Notably, as
compared to antibiotics alone, a significant increase in activity
was observed for all the tested peptide antibiotic physical
mixtures (Table S4, Supporting Information). Significant
enhancement in activity was observed for the combination of
5a with kanamycin showing MICs of 4 and 8 μg/mL against
MRSA (ATCC BAA 1556) and P. aeruginosa (ATCC 27883),
respectively, and demonstrating a 64- and 32-fold enhancement, respectively, when compared with kanamycin alone. A
combination of 5a with polymyxin B showed an MIC value of
2 μg/mL against MRSA with a 32-fold improvement versus
polymyxin B alone.
Vancomycin and daptomycin are peptide-based antibiotics
used for the treatment of Gram-positive infections. Vancomycin is a frontline glycopeptide, and daptomycin is a cyclic
lipopeptide antibiotic. Gram-negative pathogens have an
additional outer membrane that coats the cell surface. This
membrane is highly resistant and impermeable to vancomycin
and daptomycin, which limits their access to Gram-negative
pathogens and makes them least susceptible to vancomycin
and daptomycin compared with Gram-positive ones.94,95
Interestingly, although vancomycin and daptomycin are
active against Gram-positive bacteria exclusively, the physical
mixture of peptide 5a with vancomycin and daptomycin

Article

showed a significant activity against Gram-negative bacteria.
The vancomycin combination showed MICs of 4, 8, and 8 μg/
mL against K. pneumoniae (ATCC BAA-1705), P. aeruginosa
(ATCC 27883), and E. coli (ATCC 25922), respectively, while
the daptomycin combination demonstrated MIC values of 4−
16 μg/mL against the same strains. Both vancomycin and
daptomycin in combination with 5a displayed a 32−128-fold
enhancement in the antibacterial efficacy against Gramnegative strains compared with antibiotics alone.
Another interesting result was observed for combining
clindamycin with 5a, which showed 256- and 128-fold
enhancement in activity against K. pneumoniae (ATCC BAA1705) and P. aeruginosa (ATCC 27883), respectively, with
MIC values of 2−4 μg/mL. A combination of clindamycin
with 5a also showed a 16-fold enhancement in activity against
E. coli (ATCC 25922) when compared with clindamycin alone.
Combinations of ciprofloxacin and metronidazole with 5a
showed a 32-fold enhancement in activity against K. pneumoniae (ATCC BAA-1705) with an MIC value of 8 μg/mL, while
the metronidazole combination with 5a displayed an MIC
value of 2 μg/mL against MRSA, showing a 16-fold
improvement when compared with metronidazole alone.
Similarly, a 16-fold enhancement in activity was observed for
a combination of tetracycline with 5a (MIC value of 2 μg/mL)
when compared with tetracycline alone against P. aeruginosa
(ATCC 27883).
In combination with 5a, kanamycin, metronidazole,
ciprofloxacin, levofloxacin, and tetracycline showed a remarkable 8-fold enhancement in activity against E. coli (ATCC
25922) (MICs in the range of 1−16 μg/mL) as compared to
the antibiotics alone. On the other hand, against K. pneumoniae
(ATCC BAA-1705), tetracycline, levofloxacin, kanamycin, and
meropenem demonstrated an 8-fold improvement in the
antibacterial activity (MIC values of 2−8 μg/mL) in
combination with 5a versus the antibiotics alone. The
combination of ciprofloxacin with 5a displayed an 8- and 4fold improvement, respectively, against MRSA and P.
aeruginosa (ATCC 27883), when compared with the antibiotic
alone, with MIC values of 2 and 0.125 μg/mL. A combination
of meropenem and 5a also showed an 8-fold enhancement in
activity against P. aeruginosa when compared with meropenem.
The rest of the combinations showed improvement in the
antibacterial efficacy of the tested antibiotics with a 2−4-fold
enhancement in activity against tested strains.
The physical mixture of peptide 6a with antibiotics also
showed enhancement in activity against all the tested strains
(Table S5, Supporting Information). Significant enhancement
in activity (64-fold) was observed for a combination of 6a and
clindamycin with an MIC value of 8 μg/mL against K.
pneumoniae (BAA-1705) and P. aeruginosa (ATCC 27883),
when compared with clindamycin alone. A remarkable
enhancement in antibacterial activity was also observed for
the combination of 6a with kanamycin (64-fold against MRSA
and P. aeruginosa (ATCC 27883) (MIC of 4 μg/mL)) as
compared to kanamycin alone.
Similar to 5a, the physical mixture of peptide 6a with
vancomycin and daptomycin showed significant improvement
in activity against Gram-negative bacteria. The vancomycin
combination showed MIC values of 8−16 μg/mL with a 16−
32-fold improvement against K. pneumoniae (ATCC BAA1705), E. coli (ATCC 25922), and P. aeruginosa (ATCC
27883) when compared with vancomycin alone. The
daptomycin combination demonstrates MIC values of 8−16
H
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Table 5. The Synergistic Effect of the Peptide 5a/Antibiotic Combination
MIC (μg/mL)
combination
[R5W4] + tetracycline

[R5W4] + tobramycin

[R5W4] + clindamycin

[R5W4] + kanamycin

[R5W4] + levofloxacin

[R5W4] + ciprofloxacin

[R5W4] + polymyxin B

[R5W4] + metronidazole

[R5W4] + meropenem

[R5W4] + vancomycin

[R5W4] + daptomycin

bacterial strain

antibiotic in combination

antibiotic alone

FIC antibiotic

FICIb

integrative category

S. aureus (ATCC BAA-1556)
P. aeruginosa (ATCC 27883)
E. coli (ATCC 25922)
K. pneumoniae (ATCC BAA-1705)
S. aureus (ATCC BAA-1556)
P. aeruginosa (ATCC 27883)
E. coli (ATCC 25922)
K. pneumoniae (ATCC BAA-1705)
S. aureus (ATCC BAA-1556)
P. aeruginosa (ATCC 27883)
E. coli (ATCC 25922)
K. pneumoniae (ATCC BAA-1705)
S. aureus (ATCC BAA-1556)
P. aeruginosa (ATCC 27883)
E. coli (ATCC 25922)
K. pneumoniae (ATCC BAA-1705)
S. aureus (ATCC BAA-1556)
P. aeruginosa (ATCC 27883)
E. coli (ATCC 25922)
K. pneumoniae (ATCC BAA-1705)
S. aureus (ATCC BAA-1556)
P. aeruginosa (ATCC 27883)
E. coli (ATCC 25922)
K. pneumoniae (ATCC BAA-1705)
S. aureus (ATCC BAA-1556)
P. aeruginosa (ATCC 27883)
E. coli (ATCC 25922)
K. pneumoniae (ATCC BAA-1705)
S. aureus (ATCC BAA-1556)
P. aeruginosa (ATCC 27883)
E. coli (ATCC 25922)
K. pneumoniae (ATCC BAA-1705)
S. aureus (ATCC BAA-1556)
P. aeruginosa (ATCC 27883)
E. coli (ATCC 25922)
K. pneumoniae (ATCC BAA-1705)
S. aureus (ATCC BAA-1556)
P. aeruginosa (ATCC 27883)
E. coli (ATCC 25922)
K. pneumoniae (ATCC BAA-1705)
S. aureus (ATCC BAA-1556)
P. aeruginosa (ATCC 27883)
E. coli (ATCC 25922)
K. pneumoniae (ATCC BAA-1705)

0.0625
4.00
1.00
2.00
0.125
0.125
2.00
2.00
0.0312
8.00
4.00
2.00
NDa
8.00
8.00
8.00
1.00
0.125
8.00
8.00
2.00
0.125
NDa
16.0
2.00
0.125
0.25
0.125
2.00
8.00
NDa
8.00
NDa
0.125
NDa
4.00
0.500
16.0
8.00
32.0
NDa
32.0
NDa
8.00

0.250
32.0
8.00
16.0
0.500
0.500
8.00
16.0
0.125
512
64.0
512
256
256
32.0
64.0
4.00
1.00
64.0
64.0
16.0
0.500
64.0
256
64.0
1.00
2.00
1.00
32.0
32.0
128
256
2.00
1.00
1.00
16.0
1.00
256
256
512
2.00
512
>128
512

0.25
0.125
0.125
0.125
0.250
0.250
0.250
0.125
0.249
0.016
0.063
0.0039
NDa
0.0313
0.250
0.125
0.25
0.125
0.125
0.125
0.125
0.250
NDa
0.0625
0.0313
0.125
0.125
0.125
0.063
0.250
NDa
0.0313
NDa
0.125
NDa
0.250
0.500
0.0630
0.0313
0.0625
NDa
0.0630
NDa
0.0156

0.500
0.375
0.375
0.375
0.500
0.500
0.500
0.375
0.499
0.266
0.313
0.254
NDa
0.281
0.500
0.375
0.500
0.375
0.375
0.375
0.625c
0.500
NDa
0.313
0.531c
0.375
0.375
0.375
0.563c
0.500
NDa
0.281
NDa
0.375
NDa
0.500
0.750
0.313
0.531c
0.563c
NDa
0.313
NDa
0.516c

synergy
synergy
synergy
synergy
synergy
synergy
synergy
synergy
synergy
synergy
synergy
synergy
NDa
synergy
synergy
synergy
synergy
synergy
synergy
synergy
partial synergy
synergy
NDa
synergy
partial synergy
synergy
synergy
synergy
partial synergy
synergy
NDa
synergy
NDa
synergy
NDa
synergy
partial synergy
synergy
partial synergy
partial synergy
NDa
synergy
NDa
partial synergy

a

ND, not determined. bFIC of the peptide in combination is 0.25 (peptide concentration equivalent to one-fourth of its MIC). cFIC of the peptide
in combination is 0.5 (peptide concentration equivalent to one-half of its MIC); all experiments were performed in triplicate.

μg/mL against the same strains with a 32−64-fold enhancement versus daptomycin alone.
A combination of 6a with metronidazole or polymyxin B
displayed a 16-fold improvement against MRSA with MICs of
2 and 4 μg/mL, respectively. Moreover, a combination of 6a
with meropenem demonstrated a 15-fold enhancement in
activity against E. coli 25922 with an MIC value of 0.065 μg/
mL when compared with meropenem alone. Furthermore, the
metronidazole and ciprofloxacin physical mixture with peptide
6a showed an MIC value of 16 μg/mL and a 16-fold
improvement in activity against K. pneumoniae (ATCC BAA1705) when compared with parent antibiotics alone.

In a similar trend, kanamycin, metronidazole, ciprofloxacin,
levofloxacin, and clindamycin showed an 8-fold enhancement
in activity compared to the antibiotics alone against E. coli
(ATCC 25922) when combined with 6a (MIC range of 4−16
μg/mL). On the other hand, the combination of tetracycline,
metronidazole, and meropenem with 6a demonstrated an 8fold improvement in the antibacterial activity compared to the
parent antibiotics alone, with MIC values of 4, 4, and 0.125
μg/mL, respectively, against P. aeruginosa (ATCC 27883). A
combination of kanamycin with 6a displayed an 8-fold
improvement with MIC values of 8 μg/mL against K.
pneumoniae (ATCC BAA-1705). The rest of the combinations
I
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Table 6. The Synergistic Effect of the Peptide 6a/Antibiotic Combination
MIC (μg/mL)
combination
[R6W4] + tetracycline

[R6W4] + tobramycin

[R6W4] + clindamycin

[R6W4] + kanamycin

[R6W4] + levofloxacin

[R6W4] + ciprofloxacin

[R6W4] + polymyxin B

[R6W4] + metronidazole

[R6W4] + meropenem

[R6W4] + vancomycin

[R6W4] + daptomycin

bacterial strain

antibiotic in combination

antibiotic alone

FIC antibiotic

FICIb

integrative category

S. aureus (ATCC BAA-1556)
P. aeruginosa (ATCC 27883)
E. coli (ATCC 25922)
K. pneumoniae (ATCC BAA-1705)
S. aureus (ATCC BAA-1556)
P. aeruginosa (ATCC 27883)
E. coli (ATCC 25922)
K. pneumoniae (ATCC BAA-1705)
S. aureus (ATCC BAA-1556)
P. aeruginosa (ATCC 27883)
E. coli (ATCC 25922)
K. pneumoniae (ATCC BAA-1705)
S. aureus (ATCC BAA-1556)
P. aeruginosa (ATCC 27883)
E. coli (ATCC 25922)
K. pneumoniae (ATCC BAA-1705)
S. aureus (ATCC BAA-1556)
P. aeruginosa (ATCC 27883)
E. coli (ATCC 25922)
K. pneumoniae (ATCC BAA-1705)
S. aureus (ATCC BAA-1556)
P. aeruginosa (ATCC 27883)
E. coli (ATCC 25922)
K. pneumoniae (ATCC BAA-1705)
S. aureus (ATCC BAA-1556)
P. aeruginosa (ATCC 27883)
E. coli (ATCC 25922)
K. pneumoniae (ATCC BAA-1705)
S. aureus (ATCC BAA-1556)
P. aeruginosa (ATCC 27883)
E. coli (ATCC 25922)
K. pneumoniae (ATCC BAA-1705)
S. aureus (ATCC BAA-1556)
P. aeruginosa (ATCC 27883)
E. coli (ATCC 25922)
K. pneumoniae (ATCC BAA-1705)
S. aureus (ATCC BAA-1556)
P. aeruginosa (ATCC 27883)
E. coli (ATCC 25922)
K. pneumoniae (ATCC BAA-1705)
S. aureus (ATCC BAA-1556)
P. aeruginosa (ATCC 27883)
E. coli (ATCC 25922)
K. pneumoniae (ATCC BAA-1705)

0.0625
8.00
0.500
2.00
0.0625
NDa
NDa
4.00
0.031
8.00
4.00
8.00
4.00
4.00
4.00
16.0
NDa
0.125
8.00
8.00
4.00
0.125
8.00
16.0
4
NDa
0.125
0.031
2.00
4.00
16.0
16.0
NDa
0.250
0.125
NDa
0.250
8.00
16.0
32.0
NDa
8.00
NDa
64.0

0.250
32.0
8.00
16.0
0.500
0.500
8.00
16.0
0.125
512
64.0
512
256
256
32.0
64.0
4.00
1.00
64.0
64.0
16.0
0.500
64.0
256
64.0
1.00
2.00
1.00
32.0
32.0
128
256
2.00
1.00
1.00
16.0
1.00
256
256
512
2.00
512
>128
512

0.250
0.250
0.063
0.125
0.125
NDa
NDa
0.250
0.248
0.0160
0.063
0.0160
0.0156
0.0156
0.125
0.250
NDa
0.125
0.125
0.125
0.250
0.250
0.125
0.0625
0.063
NDa
0.063
0.031
0.063
0.125
0.125
0.063
NDa
0.250
0.125
NDa
0.250
0.0313
0.0630
0.0625
NDa
0.0156
NDa
0.125

0.500
0.500
0.313
0.375
0.375
NDa
NDa
0.500
0.498
0.516c
0.313
0.266
0.516c
0.266
0.375
0.500
NDa
0.375
0.375
0.375
0.750 c
0.500
0.375
0.313
0.563c
NDa
0.313
0.281
0.563c
0.375
0.625c
0.313
NDa
0.500
0.375
NDa
0.500
0.531c
0.563c
0.313
NDa
0.516c
NDa
0.375

synergy
synergy
synergy
synergy
synergy
NDa
NDa
synergy
synergy
synergy
synergy
synergy
partial synergy
synergy
synergy
synergy
NDa
synergy
synergy
synergy
partial synergy
synergy
synergy
synergy
partial synergy
NDa
synergy
synergy
partial synergy
synergy
partial synergy
synergy
NDa
synergy
synergy
NDa
synergy
partial synergy
partial synergy
synergy
NDa
partial synergy
NDa
synergy

a

ND, not determined. bFIC of the peptide in combination is 0.25 (peptide concentration equivalent to one-fourth of its MIC). cFIC of the peptide
in combination is 0.5 (peptide concentration equivalent to one-half of its MIC); all experiments were performed in triplicate.

showed improvement in the antibacterial efficacy of the tested
antibiotics with a 2−4-fold enhancement in activity against
tested strains.
The nature of improvement in activity in combination is not
clear at this time. Considering the remarkable membrane
disruption potential of lead cyclic peptides as indicated, it
seems that the peptide compromises the membrane barrier,
which eventually facilitates the translocation of the antibiotics
inside the cell and exerts cell death. Moreover, a combination
of the peptide and antibiotics might have generated a unique
complex via various chemical interactions that could have a
distinct antibacterial mechanism. Further studies are required

to determine the nature of the antibacterial enhancement of
the activity of a combination versus the parent analogs.
2.4.2. Synergistic Studies. Based on the promising
antibacterial enhancement results observed for the physical
mixture of the lead peptides 5a and 6a in combination with
various antibiotics, we conducted a more extensive synergistic
study on the physical mixture combinations. The checkerboard
assay was performed to study the synergistic interaction
between lead peptides (5a and 6a) and 11 commercially
available antibiotics in combinations. This study aimed to
compare the influence of synergistic combinations on the
antibacterial efficacy against the individual peptide or antiJ
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biotic. The comparison is represented by the fractional
inhibitory concentration index (FICI) value, which classifies
the combined impact of the two tested compounds. Selected
antibiotics were tested as 11 dose points of two-fold serial
dilutions across the assay plate in combination with seven
points of two-fold serial dilution of the peptides down the
assay plate. Two-fold serial dilutions for antibiotics and
peptides were performed individually to determine the MIC
value for each tested compound.
Table 5 depicts the data obtained from the checkerboard
assay for peptide 5a along with 11 commercial antibiotics to
determine the ideal concentration of both the peptide and
antibiotics to afford an optimal antibacterial activity in
combination. The concentrations of peptide 5a started from
its MIC and were then subjected to two-fold serial dilutions (a
total of 7 points).
Tetracycline, tobramycin, clindamycin, kanamycin, levofloxacin, polymyxin B, metronidazole, and vancomycin had
remarkable improvement in antimicrobial activity in combination with the 5a concentration equivalent to one-fourth of its
MIC (4-fold improvement, FICpeptide = 0.25). A summary of
the results is described here.
The clindamycin combination showed significant enhancement against tested Gram-negative strains. Clindamycin
displayed 256-fold reduced MIC values compared to individual
antibiotics against clinically resistant K. pneumoniae (ATCC
BAA-1705) with an FICI value of 0.254. Clindamycin
demonstrated a 64- and 16-fold improvement and FICI values
of 0.266 and 0.313 against P. aeruginosa (27883) and E. coli
(ATCC 25922), respectively. Clindamycin, ciprofloxacin, and
metronidazole showed significant improvement against clinically resistant K. pneumoniae (ATCC BAA-1705) with FICI
values of 0.254, 0.313, and 0.281, showing 256, 16, 32-fold
improved MIC values compared to individual antibiotics,
respectively. Moreover, kanamycin, vancomycin, and daptomycin displayed significant enhancement in activity against P.
aeruginosa (ATCC 27883) with a 32-, 16-, and 16-fold
enhancement in antibiotic activity and FICI values of 0.281,
0.313, and 0.313, respectively.
Tetracycline, tobramycin, kanamycin, levofloxacin, and
polymyxin B showed an 8-fold enhancement in antibiotic
activity with a FICI value of 0.375 against K. pneumoniae
(ATCC BAA-1705), while meropenem showed a 4-fold
improvement with an FICI of 0.5. Tetracycline, levofloxacin,
and polymyxin showed an 8-fold improvement against E. coli
(ATCC 25922) with an FICI of 0.375, while a 4-fold
enhancement and an FICI of 0.5 were observed for tobramycin
and kanamycin.
For the P. aeruginosa (ATCC 27883) strain, tetracycline,
levofloxacin, polymyxin B, and meropenem demonstrated an 8fold improvement with an FICI value of 0.375, while
tobramycin, ciprofloxacin, and metronidazole showed a 4fold enhancement. Furthermore, a 4-fold improvement was
observed for each of tetracycline, tobramycin, clindamycin, and
levofloxacin against multidrug-resistant Gram-positive MRSA
strains.
Some antibiotics showed partial synergy due to the minor
improvement for the peptide MIC in combination despite the
remarkable improvement in some of the tested antibiotics’
efficacy (peptide concentration equivalent to one-half of its
MIC with FICI = 0.5- and 2-fold improvement). For example,
ciprofloxacin, polymyxin B, metronidazole, and vancomycin
displayed a 2−32 improvement of antibiotic MICs and partial
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synergy in combination against MRSA. In the same way,
despite the significant improvement in antibiotic activity with a
16−32 improvement in MICs, vancomycin demonstrated
partial synergy against E. coli (ATCC 25922) and K.
pneumoniae (ATCC BAA-1705) with FICI values of 0.531
and 0.563, respectively. Daptomycin showed partial synergistic
interactions in combination with 5a with an FICI value of
0.516 and 64-fold reduced MIC values compared to the parent
antibiotic against K. pneumoniae (ATCC BAA-1705).
Checkerboard assay results for peptide 6a in combination
with the antibiotics are presented in Table 6. In combination
with 6a at a concentration equivalent to one-fourth of its MIC
(4-fold improvement, FICpeptide = 0.25), clindamycin, kanamycin, ciprofloxacin, polymyxin B, tetracycline, and levofloxacin
exhibited significant improvement in the antimicrobial activity
(Table 6). A summary of the results is described here.
The clindamycin combination with 6a showed significant
enhancement in activity against E. coli (ATCC 25922) and K.
pneumoniae (ATCC BAA-1705). Clindamycin demonstrated a
64-fold improvement in MIC values when combined with 6a
compared to antibiotics alone against clinically resistant K.
pneumoniae (ATCC BAA-1705) with an FICI value of 0.266
while displaying a 16-fold MIC improvement versus
clindamycin alone with an FICI value of 0.313 against E. coli
(ATCC 25922).
Moreover, for polymyxin B in combination with 6a, a 32fold (FICI = 0.281) and 16-fold (FICI = 0.313) improvement
in MIC against K. pneumoniae (ATCC BAA-1705) and E. coli
(ATCC 25922), respectively, was observed when compared
with the antibiotic alone. Kanamycin displayed a 64-fold MIC
improvement with an FICI value of 0.266 against P. aeruginosa
(ATCC 27883). Ciprofloxacin, metronidazole, and vancomycin showed remarkable improvement when combined with 6a
against clinically resistant K. pneumoniae (ATCC BAA-1705)
with a 16-fold improvement in MIC values compared to the
parent antibiotics and FICI values of 0.313. Tetracycline
showed a 16-fold enhancement in activity against E. coli
(ATCC 25922) with an FICI value of 0.313. Tobramycin
displayed an 8-fold improvement in antibiotic activity
compared with the antibiotic alone, with an FICI value of
0.375 against the clinically resistant Gram-positive MRSA
strain.
Ciprofloxacin, kanamycin, levofloxacin, and meropenem
showed an 8-fold enhancement in antibiotic activity when
compared with the parent antibiotic and with an FICI value of
0.375 against E. coli (ATCC 25922). Tetracycline, levofloxacin,
and daptomycin in combination with 6a showed an 8-fold
improvement against K. pneumoniae (ATCC BAA-1705)
compared with the antibiotics alone with an FICI of 0.375,
while a 4-fold enhancement in activity and an FICI of 0.5 were
observed for tobramycin and kanamycin.
For P. aeruginosa (ATCC 27883), levofloxacin and
metronidazole demonstrated an 8-fold improvement versus
antibiotics alone with an FICI value of 0.375, while
tetracycline, ciprofloxacin, and meropenem showed a 4-fold
enhancement in activity and an FICI of 0.5. An about 4-fold
improvement was observed for tetracycline, clindamycin, and
vancomycin against the multidrug-resistant Gram-positive
MRSA strain compared with the antibiotics alone.
Partial synergy was observed for some of the tested
antibiotics in combination with 6a at one-half of the peptide
MIC concentration with FIC = 0.5- and 2-fold improvement.
Some antibiotics displayed a 4−64-fold enhancement in
K
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activity of antibiotic MICs and partial synergy in combination.
Kanamycin, ciprofloxacin, polymyxin B, and metronidazole
showed partial synergistic interactions with peptide 6a in
combination with FICI values of 0.516, 0.750, 0.563, and 0.563
against MRSA, respectively.
Despite the significant improvement in antibiotic activity
with a 32−64 improvement in antibiotics’ MICs of
clindamycin, vancomycin, and daptomycin, they demonstrated
partial synergy against P. aeruginosa (ATCC 27883) with FICI
values of 0.516, 0.531, and 0.516, respectively. Vancomycin
and metronidazole showed partial synergistic interactions with
6a against E. coli (ATCC 25922) with FICI values of 0.563 and
0.625 and 8−16-fold reduced MIC values compared to
individual antibiotics.
2.5. Cytotoxicity Studies. 2.5.1. Hemolytic Activity. The
cytotoxicity of all the synthesized cyclic peptides (2a−7d) was
examined by conducting a hemolytic assay using human red
blood cells (hRBCs). In general, peptides having a higher
number of W residues as compared to R residues displayed
high toxicity, as summarized in Table 1. For instance, 2b,
composed of three W, was found to be more toxic than 2a,
which has two W. Similarly, among the peptides composed of
three (3a−3e), four (4a−4c), five (5a−5e), six (6a−6d), and
seven (7a−7d) R and a varying number of W, the maximum
toxicity was observed for peptides having a low cationic
charge/hydrophobic ratio (2a, 2b, 3b, 3c, 4a−4c, 5c, 5d, 6c,
and 6d). Thus, it seems that as the hydrophobic bulk increases,
the ability of the peptide to discriminate between the anionic
bacterial surface and the zwitterionic mammalian membrane
decreases. These outcomes are in agreement with many
previous reports, 96,97 including ours. Furthermore, we
calculated the therapeutic index for MRSA cells by dividing
HC50 values with the MICs against MRSA (Table 1). The
maximum therapeutic index was observed for 5a, 5b, 6a, and
6b with values of 85.0, 57.5, 33.1, and 31.9, respectively.
2.5.2. Cell Viability Assay. To further examine the toxicity
of the lead peptide 5a, we conducted cytotoxicity screening
against normal lung (MRC-5), kidney (HEK-293), liver
(HepaRG), and human skin fibroblast cells (HeKa) cells
(Figure 2). At a 100 μg/mL concentration, 5a showed
negligible cytotoxicity against lung (98% cell viability) and liver
cells (91% cell viability). However, comparatively higher
cytotoxicity was observed against kidney and skin cells with
75 and 70% cell viability, respectively. Quite a similar trend of
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cytotoxicity was observed at the highest experimental
concentration of 250 μg/mL with minimal cytotoxicity against
liver (77% cell viability) and lung cells (69% cell viability) and
comparatively low cell viability for kidney (57% cell viability)
and skin cells (51% cell viability). The therapeutic index was
calculated based on HC50/MIC against MRSA in Table 1. If
we calculate the therapeutic index based on the cytotoxicity
assay in skin cells versus MIC against MRSA, the TI will be
approximately 63. However, the therapeutic index values will
be much higher for lung, kidney, and liver cells since cell
viability is much higher even at 250 μg/mL. Overall, like
hemolytic data, the cytotoxicity results also revealed a good
selectivity profile of 5a since minimal cytotoxicity was observed
at MIC values.
2.6. Bactericidal Kinetic Assay. As compared to conventional antibiotics, AMPs are known to exert bacterial killing at
a rapid pace. To examine whether this ability is also inherent to
the lead peptide 5a, the viability of exponentially growing
antibiotic-resistant strains of S. aureus and E. coli was
determined by conducting a 4 h time-kill assay (Figure 3).
Peptide 5a exerted a time-dependent killing action against
MRSA and eliminated almost all bacterial cells in 3.5 h at the
MIC and in 2 h at 4× the MIC. On the other hand, peptide 5a
at the MIC displayed comparatively less rapid action against E.
coli as complete eradication of the bacteria was not achieved
even after a 4 h treatment. However, at 4× the MIC, a rapid
killing action, comparable to MRSA, was observed with
complete eradication of E. coli cells after a 2 h treatment.
Noticeably, against MRSA and E. coli, the kinetics of
bactericidal action of peptide 5a was closely matched with
the peptide-based antibiotics daptomycin and polymyxin B.
However, it was found to be superior to the conventional
antibiotic ciprofloxacin. Overall, bactericidal kinetic study
results revealed the rapid killing action of peptide 5a against
both MRSA and E. coli. Many previous reports on AMPs with
rapid bactericidal action demonstrated membrane disruption
as their preferred mode of action. Thus, the rapid bacterial
killing effect of peptide 5a suggests that AMP antibacterial
action might be mediated through membrane perturbation.
2.7. Membrane Disruption Action. 2.7.1. Calcein Dye
Leakage Assay. Membrane disruption is considered a
preferred mode of action for most naturally occurring and
synthetic AMPs. To study the membranolytic action of the
lead cyclic peptide 5a, we performed a calcein dye leakage
experiment by employing negatively charged and zwitterionic
calcein-encapsulated lipid vesicles, which mimic the outer
surface of the bacterial and mammalian cell membrane,
respectively. Peptide 5a induced calcein dye leakage that was
measured at various concentration levels ranging from 5 to 50
μg/mL at different time intervals (Figure 4). The results
demonstrate a concentration-dependent leakage of the dye
upon treatment of calcein-encapsulated bacterial membranemimicking liposomes with peptide 5a. At 5 μg/mL, peptide 5a
induced around 25% of dye release after 100 min of
incubation. With the increase in the concentration of peptide
5a, a sharp increase in the amount of dye leakage was observed.
At the highest experimental concentration (50 μg/mL),
peptide 5a exerted 100% dye leakage after 90 min of
incubation.
Interestingly, peptide 5a induced a nonsignificant amount of
dye leakage when incubated with liposomes mimicking the
mammalian membrane, as indicated by around 13% dye
leakage after 100 min. Compared to peptide 5a, daptomycin at

Figure 2. Cytotoxicity assay of the lead cyclic peptide 5a. The results
represent the data obtained from the experiments performed in
triplicate (incubation for 24 h). DMSO (30%) was used as a positive
control. The cells treated with DMSO (30%) showed 7−11% cell
viability compared to nontreated (NT) cells having 100% cell
viability.
L
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Figure 3. Bactericidal kinetics of the lead cyclic peptide (5a) and standard antibiotics (daptomycin, polymyxin B, and ciprofloxacin) against MRSA
(A1−A3) and E. coli (B1−B3) at the MIC and 4× the MIC. The data obtained are from the experiments performed in triplicate.

Figure 4. Concentration-dependent leakage of the calcein dye from bacterial membrane-mimicking (A1,A2) and mammalian membrane-mimicking
(B1,B2) liposomes. 5a (A1,B1) and daptomycin (A2,B2). The data obtained are from the experiments performed in triplicate.
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Figure 5. FE-SEM images of MRSA (A1,B1) and E. coli (A2,B2). Mid-logarithmic-phase bacterial cells were incubated with 5a (A2,B2) at a final
concentration of 4× the MIC for 1 h. The control (A1,A2) was done without peptides.

Figure 6. Resistance induction after 18 repeated times of exposure of the lead cyclic peptide (5a) and standard antibiotics (daptomycin, polymyxin
B, and ciprofloxacin) against (A1) S. aureus (ATCC 29213), (A2) MRSA (ATCC BAA-1556), (B1) E. coli (ATCC 25922), and (B2) E. coli
(ATCC BAA-2452). The data represent the experiments performed in triplicate.

50 μg/mL resulted in mild dye leakage when incubated with
liposomes mimicking the bacterial membrane as suggested by

only 42% of dye release observed after 100 min of incubation.
These results agree with the previous reports on the lipid
N
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membrane interaction of daptomycin. A negligible amount of
dye leakage (around 7%) was observed for daptomycin (50
μg/mL) when incubated with mammalian membrane-mimicking liposomes for 100 min. The calcein dye leakage
experiments indicated that, like most native AMPs, the
antibacterial activity of peptide 5a depends on its ability to
destabilize the target bacterial membrane.
2.7.2. Field-Emission Scanning Electron Microscopy (FESEM). To further confirm the membranolytic action of the lead
peptide 5a, we examined the treated MRSA and E. coli cells
using FE-SEM. The SEM micrographs explicitly indicate the
membrane-damaging properties of peptide 5a against both
MRSA and E. coli. The untreated cells exhibit a regular size and
shape with bright and smooth surfaces (Figure 5A1,B1).
Treatment of bacterial cells with peptide 5a at 4× the MIC
exerted intense cell-specific morphological changes. While the
loss of membrane fluidity is quite evident for both MRSA and
E. coli, strong membrane atrophy was observed for E. coli.
These data point toward the different modes of membrane
disruption of peptide 5a against MRSA and E. coli.
2.8. Resistance Development Study. Due to the
extraordinary ability of bacteria to develop resistance, the
effectiveness of conventional antibiotics in treating infections
caused by resistant pathogens is continuously diminishing.
Therefore, resistance development is considered one of the
potential menaces associated with the clinical use of conventional antibiotics. Considering the membrane disruption effect
of peptide 5a, as indicated by the results of the calcein dye
leakage experiment and SEM images, we anticipated that,
similar to other peptide-based antibacterial agents, it will be
difficult for bacteria to develop resistance. To examine the
ability of bacteria to develop resistance against peptide 5a, we
performed resistance acquisition studies using resistant and
susceptible strains of S. aureus and E. coli. To make a
comparative analysis, S. aureus strains were treated with
daptomycin and ciprofloxacin, and E. coli strains were treated
with polymyxin B and ciprofloxacin. After each successive
exposure of bacteria with different test specimens, a new MIC
was determined as an indicator of the resistance development
(Figure 6). Interestingly, similar to the peptide-based antibiotics (daptomycin and polymyxin B), negligible changes in
the MICs were observed for peptide 5a against all the tested
bacterial strains. However, contrary to that, a sharp increase in
the MICs of ciprofloxacin was observed against all the tested
bacterial strains. Taken together, these results indicate that
peptide 5a holds a remarkable therapeutic potential to treat
infections caused by resistant strains and therefore demand
further investigation.
2.9. Plasma Stability. Most of the naturally occurring
AMPs are structurally linear and relatively large molecules.
They, therefore, have a number of scissile amide bonds, which
makes them an easy target for many peptidases. Consequently,
the inherent enzymatic instability renders these potent
antimicrobial molecules inactive in the intended biological
environment. Therefore, this issue needs to be resolved for the
success of peptide-based therapeutics in clinical settings. In this
respect, we examined the stability of peptide 5a in human
blood plasma for up to 24 h (Figure 7). After 30 min of
incubation, around 79% of the intact peptide 5a was observed.
Moreover, after 2 h of incubation, around 56% of the peptide
remains undegraded. Around 25% of the intact peptide 5a was
observed after 24 h of incubation. The stability study results
indicate that peptide 5a has a half-life (t1/2) of approximately 3
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Figure 7. In vitro enzymatic stability assay of the lead cyclic peptides
5a in human plasma. The data represent the percentage of
undegraded peptides measured using Q-TOF LC/MS as the area
under the curve in the extracted ion chromatogram. The data
obtained are from three independent experiments.

h. It appears that head-to-tail cyclization of the peptides
imparts extra plasma stability.

3. CONCLUSIONS
A library of cyclic amphiphilic peptides was designed and
synthesized via solid-phase peptide synthesis. The synthesized
library consisted of R and W residues as a recurring sequence
and an ordered manner [RnWn] (n = 2−7) by systematically
changing the number of R and W residues to study the impact
of the hydrophilic/hydrophobic ratio, charge, and ring size on
antibacterial activity. The minimum inhibitory concentration
(MIC) values for all synthesized peptides were measured
against multidrug-resistant and nonresistant Gram-positive and
Gram-negative bacterial strains. The antibacterial activity was
determined against various bacterial strains, including ESKAPE
pathogens, and the minimum bactericidal concentration
(MBC) was investigated for the most promising peptides.
Among all the synthesized peptides, 5a showed significant
antibacterial activity alone and in combination with commercial antibiotics. Peptide 5a showed remarkable improvement in
a physical mixture combination (1:1 w/w) for antibiotic
efficacy against all tested strains. Furthermore, 5a displayed
synergistic interactions with significant improvement when
combined with tetracycline, tobramycin, clindamycin, kanamycin, levofloxacin, polymyxin B, metronidazole, and
vancomycin. Hemolysis and cytotoxicity data demonstrated
the selectivity of 5a against bacteria versus mammalian cells.
The membranolytic effect of 5a was shown using a calcein dye
leakage experiment and SEM. We concluded that cyclic
peptide 5a showed promising antibacterial potential to be
further developed as an AMP with a reduced chance of
resistance development.
4. EXPERIMENTAL SECTION
4.1. Materials. Tryptophan-loaded H-Trp(Boc)-2-chlorotrityl
resin and Fmoc-amino acid building blocks, Fmoc-Arg(Pbf)-OH
and Fmoc-Trp(Boc)-OH, were obtained from AAPPTec (Louisville,
KY, USA). Chemical reagents and solvents were purchased from
MilliporeSigma (Milwaukee, WI, USA) and used without further
purification. Final products were purified using a reversed-phase highperformance liquid chromatography (RP-HPLC) system (LC-20AP)
from Shimadzu (Canby, OR, USA), with a gradient system of
acetonitrile and water with 0.1% TFA (v/v), and a reversed-phase
preparative column (Waters XBridge, BEH130, 10 μm, 110 Å, 21.2 ×
250 mm), with a flow rate of 8 mL/min and detection at 214 nm. The
purity analysis of the peptides was conducted on an RP-HPLC system
O

https://doi.org/10.1021/acs.jmedchem.2c01469
J. Med. Chem. XXXX, XXX, XXX−XXX

Journal of Medicinal Chemistry

pubs.acs.org/jmc

(Shimadzu; LC-20ADXR) by using an analytical Phenomenex (Luna)
C18 column (4 μm, C18, 150 × 4.6 mm) with a flow rate of 1 mL/
min and detection at 214 nm. The chemical structures of the final
products were elucidated using a high-resolution MALDI-TOF
instrument (model no. GT 0264 from Bruker, Inc., Fremont, CA,
USA) with α-cyano-4-hydroxycinnamic acid as a matrix in the positive
mode.
For bacterial strains, multidrug-resistant strains Pseudomonas
aeruginosa (ATCC BAA-1744), Klebsiella pneumoniae (ATCC BAA1705), Escherichia coli (ATCC BAA-2452), Acinetobacter baumannii
(ATCC BAA-1605), and methicillin-resistant Staphylococcus aureus
(S. aureus BAA-1556) and nonresistant strains Staphylococcus aureus
(S. aureus 29213), Enterococcus faecium (ATCC 27270), Enterococcus
faecium (ATCC 700221), Enterococcus faecalis (ATCC 29212),
Enterococcus faecalis (ATCC 51575), Staphylococcus pneumoniae
(ATCC 49619), Staphylococcus pneumoniae (ATCC 51938), Bacillus
subtilis (ATCC-6633), Bacillus cereus (ATCC-13061), Pseudomonas
aeruginosa (ATCC 27883), Pseudomonas aeruginosa (ATCC 10145),
Klebsiella pneumoniae (ATCC 13883), and Escherichia coli (ATCC
25922) were obtained from American Type Culture Collection
(ATCC; USA). The media for bacterial experiments were purchased
from Hardy Diagnostics (Santa Maria, CA, USA) and are shown in
Table S1 (Supporting Information). Clinical isolates are shown in
Table S2 (Supporting Information). Ultrapure water was from a MilliQ system (Temecula, CA, USA). An MTS assay kit (98%) was
purchased from Promega (Madison, WI, USA). Single donor human
plasma K2 EDTA was purchased from Innov-Research (Novi, MI,
USA). All phospholipids and cholesterol were purchased from Avanti
Polar Lipids (Alabaster, USA). A calcein dye was obtained from
Sigma. All the mammalian cell culture supplies were purchased from
Corning (Christiansburg, VA, USA) and Fisher Scientific (Waltham,
MA, USA). All the mammalian cell and bacterial experiments were
carried out under a laminar flow hood from Labconco (Kansas City,
MO, USA). Cell culture was carried out at 37 °C with 5% CO2 in a
Forma incubator using a T-75 flask. All cells were maintained in a 5%
CO2 incubator (37 °C). The human lung fibroblast cells (MRC-5,
ATCC CCL-171), human embryonic kidney cells (HEK293, ATCC
CRL 1573), human hepatoma HepaRG cells (Gibco, HPRGC10),
and the human skin fibroblast cell line (HeKa, ATCC PCS-200-011)
were purchased from ATCC (USA). All cells were maintained in a 5%
CO2 incubator (37 °C). Human serum was purchased from SigmaAldrich. All bacterial strains employed in this study were procured
from VWR, USA, and propagated as per the recommendation of
ATCC.
4.2. Peptide Synthesis. The preloaded amino acid on resin, HTrp(Boc)-2-chlorotrityl resin, and Fmoc-amino acid building blocks
were used for synthesis on a scale of 0.3 mmol. O-(Benzotriazole-1yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate (HBTU) was
used as a coupling agent, and N,N-diisopropylethylamine (DIPEA)
was used as an activating reagent. Fmoc deprotection was achieved in
the presence of piperidine in DMF (20% v/v). The side chainprotected peptides were assembled on the tryptophan-preloaded HTrp(Boc)-2-chlorotrityl resin as described above on a scale of 0.3
mmol. After assembling the peptides on resin, the side chainprotected peptides were subjected to a TFE/acetic acid/DCM [2:1:7
(v/v/v)] cocktail for detaching the protected peptides from the resin
and were then subjected to cyclization using 1-hydroxy-7-azabenzotriazole (HOAt) (136 mg, 1 mmol) and 1,3-diisopropylcarbodiimide
(DIC) (207 μL, 1.33 mmol) in the mixture of anhydrous DMF/DCM
(5:1 v/v, 300 mL). The cyclization reaction occurred overnight under
an inert condition using nitrogen. All the protecting groups were
removed by stirring at room temperature in the presence of the
cleavage cocktail of the freshly prepared reagent R containing TFA/
thioanisole/1,2-ethanedithiol (EDT)/anisole (90:5:3:2, v/v/v/v) for
3 h. The crude product was precipitated by the addition of cold
diethyl ether. Peptides were dissolved in an acetonitrile/water mixture
to a final concentration of 20 mg/mL. Following filtration through a
0.45 μm Millipore filter, the peptides were purified using RP-HPLC
with a gradient of 0−90% acetonitrile (0.1% TFA) and water (0.1%
TFA) over 60 min with a C-18 column. The purified peptides were
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lyophilized to yield a white powder (around 100 mg). The purity of
synthesized cyclic peptides was determined using reversed-phase
analytical HPLC (Shimadzu; LC-20ADXR) and found to be ≥95%.
1 [R4W4]: HR-MS (MALDI-TOF) (m/z) [C68H88N24O8]: calcd,
1368.7422; found, 1369.7590 [M + H]+; 2a [R2W3]: HR-MS
(MALDI-TOF) (m/z) [C45H54N14O5]: calcd, 870.4402; found,
871.1137 [M + H]+; 2b [R2W4]: HR-MS (MALDI-TOF) (m/z)
[C56H64N16O6]: calcd, 1056.5195; found, 1057.3387 [M + H]+; 3a
[R3W3]: HR-MS (MALDI-TOF) (m/z) [C51H66N18O6]: calcd,
1026.5518; found, 1026.5966 [M]+; 3b [R3W4]: HR-MS (MALDITOF) (m/z) [C62H76N20O7]: calcd, 1212.6206; found, 1213.1192 [M
+ H]+; 3c [R3W5]: HR-MS (MALDI-TOF) (m/z) [C73H86N22O8]:
calcd, 1398.6444; found, 1399.9105 [M + H]+; 3d [R3W6]: HR-MS
(MALDI-TOF) (m/z) [C84H96N24O9] calcd, 1584.7792; found,
1584.7702 [M]+; 3e [R3W7]: HR-MS (MALDI-TOF) (m/z)
[C95H106N26O10]: calcd, 1770.8585; found, 1771.6164 [M + H]+;
4a [dR4W4]: HR-MS (MALDI-TOF) (m/z) C68H88N24O8: calcd,
1368.7217; found, 1369.0454 [M + H]+; 4b [R4W5]: HR-MS
(MALDI-TOF) (m/z) [C79H98N26O9]: calcd, 1554.8320; found,
1555.1560 [M + H]+, 1577.1408 [M + Na]+; 4c [R4W6]: HR-MS
(MALDI-TOF) (m/z) [C90H108N28O10]: calcd, 1740.8908; found,
1741.8152 [M + H]+; 4d [R4W7]: HR-MS (MALDI-TOF) (m/z)
[C101H118N30O11]: calcd, 1926.9701; found, 1927.9072 [M + H]+; 5a
[R5W4]: HR-MS (MALDI-TOF) (m/z) [C74H100N28O9]: calcd,
1524.8433; found, 1525.6209 [M + H]+; 5b [R5W5]: HR-MS
(MALDI-TOF) (m/z) [C85H110N30O10]: calcd, 1710.9126; found,
1710.4793 [M]+; 5c [R5W6]: HR-MS (MALDI-TOF) (m/z)
[C96H122N32O12]: calcd, 1897.1260; found, 1898.4210 [M + H]+,
1920.4116 [M + Na]+; 5d [R5W7]: HR-MS (MALDI-TOF) (m/z)
[C107H130N34O12]: calcd, 2083.0607; found, 2084.2055 [M + H]+; 6a
[R6W4]: HR-MS (MALDI-TOF) (m/z) [C80H112N32O10]: calcd,
1680.9344; found, 1680.0997 [M]+; 6b [R6W5]: HR-MS (MALDITOF) (m/z) [C91H122N34O10]: calcd, 1867.0237; found, 1866.5769
[M]+; 6c [R6W6]: HR-MS (MALDI-TOF) (m/z) [C102H132N36O12]:
calcd, 2053.0825; found, 2054.1105 [M + H]+; 6d [R6W7]: HR-MS
(MALDI-TOF) (m/z) [C113H142N38O13]: calcd, 2239.1723; found,
2240.3233 [M + H]+; 7a [R7W4]: HR-MS (MALDI-TOF) (m/z)
[C86H124N36O11]: calcd, 1837.0455; found, 1839.3871 [M + 2H]+; 7b
[R7W5]: HR-MS (MALDI-TOF) (m/z) [C97H134N38O12]: calcd,
2023.1043; found, 2023.9510 [M + H]+; 7c [R7W6]: HR-MS
(MALDI-TOF) (m/z) [C108H144N40O13]: calcd, 2209.1837; found,
2210.1507 [M + H]+; 7d [R7W7]: HR-MS (MALDI-TOF) (m/z)
[C119H154N42O14]: calcd, 2395.2630; found, 2396.2736 [M + H]+.
4.3. Antimicrobial Assays. 4.3.1. Minimum Inhibitory Concentration (MIC) Determination. The antibacterial activities of all
synthesized compounds were evaluated against Gram-positive and
Gram-negative bacteria. The selected bacterial strains were cultured
according to the guidelines of the Clinical Laboratory Standards
Institute (CLSI) guidelines. The minimum inhibitory concentration
(MIC) was determined by microbroth dilution. The minimal
concentration was determined to be at a concentration in wells in
which no visible bacterial growth was present. An aliquot of an
overnight culture of bacteria was grown in suitable media (Table S1,
Supporting Information) diluted in 1 mL of normal saline to achieve
0.5 McFarland turbidity (1.5 × 108 bacterial cell CFU/mL). A volume
of 60 μL of the 0.5 McFarland solution was added to 8940 μL of MH
media (this was a 1/150 dilution). A concentration of 512 μg/mL of
the tested peptides was prepared from a stock solution of the samples
for testing in Müller−Hinton broth MH media. An amount of 100 μL
of MH media was pipetted into the sterile 96-well plate except for the
first well. An amount of 200 μL of 512 μg/mL compound samples
was added by a pipette into the first well and serially diluted with the
MH media along sterile 96 wells using a multitip pipette except the
last well. An amount of 100 μL of aliquot of bacterial solution was
added to each well, and the plate was incubated at 37 °C for 24 h. All
experiments were conducted in triplicate.
4.3.2. Minimum Bactericidal Concentration (MBC) Determination. MBC is the lowest concentration of an antibacterial agent
required to kill a bacterium over a fixed period, such as 24 h, under a
specific set of conditions. We determined the MBC of the promising
P
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peptides (5a, 5b, 6a, and 6b) from the broth dilution of MIC tests by
subculturing them to agar plates and applying 24 h of incubation at 37
°C. The MBC was identified by determining the lowest concentration
of the antibacterial agent that reduced the viability (concentration of
peptides necessary to achieve a bactericidal effect) of the initial
bacterial inoculum by ≥99.9%.
4.3.3. The Synergistic Checkerboard Assay. A checkerboard assay
was performed in a sterile 96-well plate using a multichannel pipette
(Tables S6 and S7, Supporting Information). An aliquot of an
overnight culture of bacteria was grown in Luria broth (LB) diluted in
1 mL of normal saline to achieve 0.5 McFarland turbidity (1.5 × 108
bacterial cell CFU/mL). A volume of 60 μL of the 0.5 McFarland
solution was added to 8940 μL of MH media (this was a 1/150
dilution). The concentrations of the peptide started from its
respective MICs and were then subjected to two-fold serial dilutions
(a total of 7 points). The antibiotics’ concentration started from 128
μg/mL (11 points). Antibiotics were tested as 11 points, two-fold
serial dilutions across the assay plate (from 1 to 11 columns) in
combination with a seven (A−G)-point and two-fold serial dilution of
the peptides down the assay plate. To determine the MIC value for
each test compound, two-fold serial dilution in row H (from 1 to 11)
for antibiotics alone was performed. In column 12 (A−G) down the
assay plate, a two-fold serial dilution of the peptide alone was
performed. Assay plates were inoculated with 100 μL of bacterial
suspensions and incubated at 37 °C for 24 h.
The following equation was applied to calculate the FICI: (A)/
MICA + (B)/MICB = FICA + FICB = FICI, where (A) and (B) are the
MIC of (antibiotic + [peptide]) in combination (in a single well) and
MICA and MICB are the MIC of each compound individually. Based
on the calculated FICI value, the interaction between combinations
was categorized into four prospects synergy, partial synergy, additive
or indifference, and antagonism. FICI was interpreted as follows: FICI
≤ 0.5, synergy; 0.5 < FICI ≤ 1, partial synergy; 1 ≤ FICI < 4, additive
effect or indifference; 4 ≤ FICI antagonism. All experiments were
performed in triplicate.
4.3.4. Time-Kill Kinetics Assay. The time course of bacterial killing
was studied by exposure of overnight grown cultures of MRSA
(ATCC BAA-1556) and E. coli (ATCC BAA-2452) to the lead cyclic
peptide 5a at the MIC and 4× the MIC in Müller−Hinton media with
overnight grown bacterial culture (1.5 × 108 CFU/mL) and
incubation at 37 °C. Aliquots were sampled at 0, 0.5, 1, 2, 4, 8, 12,
18, and 24 h time points, then diluted up to 108, and plated on the
Müller−Hinton agar plate. After 24 h of incubation at 37 °C, the CFU
count was performed using a standard formula. Untreated bacterial
culture was used as a control. Data were obtained from two
independent experiments performed in triplicate.
4.3.5. Serial Passage Resistance Development Studies. We
determined the potential of susceptible and antibiotic-resistant strains
of S. aureus and E. coli to develop resistance against the lead peptide
5a. For comparative purposes, we also included different standard
antibiotics such as daptomycin, polymyxin B, and ciprofloxacin in the
study. The initial MICs of peptide 5a and standard antibiotics were
determined using the protocol mentioned in Section 4.3.1 of the
manuscript. The assays were performed in 96-well microtiter plates
using 2-fold serial dilutions of all the test specimens. From an
inoculated microtiter plate, an aliquot of the well with the highest
concentration permitting growth was taken and diluted in fresh media
to achieve the optimum bacterial load identified by comparing the
turbidity with the 0.5 McFarland standard. The bacterial suspension
was then further diluted and used for successive passage with a
resulting final concentration of 5 × 105 CFU/mL. MICs were
recorded, and the next inoculum was prepared from the well
containing the highest concentration of the drug that allowed growth.
Eighteen repeated passages were performed in an identical fashion to
that described above.
4.4. Hemolysis Assay. The hemolytic activity of all the cyclic
peptides was determined using human red blood cells (hRBC)
purchased from BioIVT, USA. The hRBC were centrifuged for 15 min
to remove the buffy coat and washed three times with phosphatebuffered saline (PBS, 100 mM NaCl, 80 mM Na2HPO4, and 20 mM
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NaH2PO4, pH 7.4). Peptide-induced hemolysis was tested in triplicate
by mixing 75 μL of the peptide solution in PBS (two-fold serial
dilution) with 75 μL of a 4% (v/v) hRBC suspension in phosphatebuffered saline. The plates were incubated for 2 h at 37 °C without
agitation and centrifuged at 1000g for 10 min. Aliquots (100 μL) of
the supernatant were transferred to 96-well plates, where hemoglobin
release was measured spectrophotometrically at 567 nm. Percent
hemolysis was calculated by the following formula:
percentage hemolysis = 100 × [(A

A 0)/(A t

A 0)]

where A represents the absorbance of the peptide sample at 567 nm
and A0 and At represent zero percent and 100% hemolysis determined
in phosphate-buffered saline and 1% Triton X-100, respectively.
4.5. Cell Viability Assay. The in vitro cytotoxicity of the lead
cyclic peptide 5a was evaluated using human lung fibroblast cells,
human embryonic kidney cells, human hepatoma HepaRG cells, and
the human skin fibroblast cell line. Cells were seeded at 10,000 per
well in 0.1 mL of media in 96-well plates 24 h prior to the experiment.
Lung and kidney cells were seeded in DMEM medium containing
FBS (10%). Liver cells were seeded in William’s E medium with a
GlutaMAX supplement. The peptides were added to each well in
triplicates at a variable concentration of 12.5−250 μg/mL and
incubated for 24 h at 37 °C in a humidified atmosphere of 5% CO2.
After the incubation period, MTS solution (20 μL) was added to each
well. Then, the cells were incubated for 2 h at 37 °C, and cell viability
was determined by measuring the absorbance at 490 nm using a
SpectraMax M2 microplate spectrophotometer. The percentage of cell
survival was calculated as [(OD value of cells treated with the test
mixture of compounds) − (OD value of culture medium)]/[(OD
value of control cells) − (OD value of culture medium)] × 100%.
4.6. Calcein Dye Leakage Assay. 4.6.1. Preparation of CalceinEncapsulated Liposomes. Large unilamellar vesicles (LUVs) of 1,2dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1,2-dioleoyl-snglycero-3-phosphoglycerol (DOPG) were prepared to mimic the
bacterial membrane (DOPC:DOPG, 7:3, w/w) or the mammalian
membrane (DOPC/Chol, 10:1, w/w) as described previously.98
Briefly, a defined amount of the lipid mixture DOPC:DOPG (7:3, w/
w) was dissolved in 2 mL of the chloroform/methanol solvent
mixture in a 100 mL round-bottom flask. The solvents were removed
under a stream of nitrogen, and the lipid film obtained was lyophilized
overnight to remove any trace of solvent. The thin lipid film was
rehydrated with calcein-containing buffer comprising 70 mM calcein,
150 mM NaCl, and 0.1 mM EDTA and adjusted to pH 7.4 by the
addition of a few drops of sodium hydroxide solution (1 M). The
liposome suspension obtained after rehydration was frozen and
thawed for five cycles and extruded 15 times through two stacked
polycarbonate filters (100 nm pore size). The free calcein was
removed by passing the liposome suspension through a Sephadex G50 column and eluting it with a buffer containing 10 mM Tris−HCl
(150 mM NaCl, 0.1 mM EDTA). After passing the liposome through
the Sephadex G-50, the liposome diameter was measured by dynamic
light scattering using a Zetasizer Nano ZS (Malvern Instruments,
USA). The average diameter of LUVs was found to be in the range of
115−120 nm.
4.6.2. Measurement of Dye Leakage. A calcein dye leakage assay
was conducted by using calcein encapsulated in large unilamellar
vesicles (LUVs). Lead peptide 5a-induced leakage of calcein from the
LUVs was monitored by measuring the fluorescence intensity at an
excitation wavelength of 490 nm and an emission wavelength of 520
nm on a SpectraMax M5 multimode microplate reader. To achieve a
final lipid concentration of 40 μM, the liposome suspension was
diluted in phosphate-buffered saline. The assay was conducted in
triplicate by mixing 50 μL of peptide solution at various
concentrations (5, 10, 20, 30, and 50 μg/mL) with 50 μL of the
liposome suspension. Calcein release from LUVs was assessed for 100
min, and the measurement was taken at an interval of 10 min. The
fluorescence intensity corresponding to 100% calcein release was
determined by adding a 10% solution (w/v) of Triton X-100. The
apparent percentage of dye leakage was calculated using the following
formula:
Q
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where F is the intensity measured at a given peptide concentration, F0
is the background intensity of the liposome sample, and Ft is the
intensity after lysis induced by Triton X-100.
4.7. SEM Analysis. Overnight grown bacterial cultures of MRSA
(ATCC BAA-1556) and E. coli (ATCC BAA-2452) were suspended
at 107 CFU/mL in 10 mM PBS, pH 7.4. Aliquots of 250 μL of the
bacterial suspension were mixed with 30 μL of peptide 5a at a final
concentration of 4× the MIC and were incubated at 37 °C for 1 h.
Controls were run without the peptides. After 30 min, the cells were
fixed with an equal volume of 4% glutaraldehyde in 0.2 M Nacacodylate buffer, pH 7.4, for 3 h at 4 °C followed by dehydration
with a graded series of ethanol and dried the sample in HMDS
(hexamethyl disilazane). Coating was done with Au/Pd at
approximately 20 nm thicknesses and observed under a scanning
electron microscope (Zeiss Sigma 300).
4.8. Plasma Stability Study. An in vitro stability study of the lead
cyclic peptide 5a was performed by using LC−MS as described
previously. For accurate quantification, we employed a mass
spectrometer (Q-TOF LC/MS) with a high resolving power. To
remove the background interference, the data were processed by using
a narrower (±0.1 m/z) extracted ion chromatogram (EIC) window.
The test peptide (100 μM) was incubated in human plasma at 37 °C
in a water bath. Aliquots (10 μL) were taken at different time points
(0, 0.5, 1, 2, 4, 6, 8, 12, and 24 h), diluted by the addition of 6 M
guanidine hydrochloride (10 μL, pH 2), and incubated at room
temperature for 30 min. Plasma proteins were precipitated by the
addition of cold ethanol (200 μL) and incubated for 30 min at −20
°C. The samples were centrifuged at 9000g for 15 min, and the
supernatant was transferred to a new tube and concentrated under a
vacuum. The samples were dissolved in water and analyzed on a
Delta-Pak (Waters) C18 column (100 Å, 5 μm, 3.9 mm × 150 mm)
at a flow rate of 0.3 mL/min using a linear gradient of aqueous
acetonitrile in the presence of formic acid (FA; 0.1%, v/v) as an ion
pair reagent. Peptides were detected by recording the absorbance at
220 nm and quantified by their peak areas of EIC. The percentage
digestion of the test peptides was calculated relative to the peak areas
at 0 min.
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